论文部分内容阅读
目的检测FXYD6蛋白在肝门胆管癌及相应癌旁远端正常胆管组织中的表达并分析其临床意义。方法应用免疫组织化学链酶亲和素-生物素-过氧化物酶复合物(SABC)法检测58例肝门胆管癌和30例远端正常胆管组织中FXYD6蛋白的表达,分析FXYD6蛋白表达与肝门胆管癌患者临床病理特征的关系。结果 FXYD6蛋白在肝门胆管癌组织中的表达阳性率明显高于其在癌旁远端正常肝门胆管组织中的表达阳性率,差异有统计学意义〔75.9%(44/58)比33.3%(10/30),χ~2=15.084,P=0.000〕。FXYD6蛋白在高、中分化肝门胆管癌组织中的表达阳性率明显高于其在低分化肝门胆管癌组织中的表达阳性率〔85.4%(35/41)比52.9%(9/17),χ~2=5.243,P=0.022〕,而FXYD6蛋白表达与肝门胆管癌患者的性别(χ~2=0.000,P=1.000)、年龄(χ~2=1.248,P=0.264)、T分期(χ~2=0.466,P=0.495)、淋巴结转移(χ~2=0.357,P=0.550)、病理分期(χ~2=0.005,P=0.944)及神经浸润(χ~2=3.016,P=0.082)均无关。结论 FXYD6在肝门胆管癌组织中的蛋白表达与其分化程度有关,其可能作为肝门胆管癌的一种新型肿瘤生物标志物。
Objective To detect the expression of FXYD6 protein in the hilar cholangiocarcinoma and adjacent normal bile duct tissues and to analyze its clinical significance. Methods The expression of FXYD6 protein in 58 cases of hilar cholangiocarcinoma and 30 cases of distal normal bile duct tissue was detected by immunohistochemical streptavidin-biotin-peroxidase complex (SABC) method. The expressions of FXYD6 protein and Relationship between clinicopathological characteristics of patients with hilar cholangiocarcinoma. Results The positive rate of FXYD6 protein expression in hilar cholangiocarcinoma was significantly higher than that in the adjacent normal hilar cholangiocarcinoma (75.9%, 44/58, 33.3% (10/30), χ ~ 2 = 15.084, P = 0.000]. The positive rate of FXYD6 protein in high and moderately differentiated hilar cholangiocarcinoma was significantly higher than that in low differentiated hilar cholangiocarcinoma 〔85.4% (35/41) vs 52.9% (9/17) (χ ~ 2 = 0.0001, P = 0.000), age (χ ~ 2 = 1.248, P = 0.264), and the correlation between the expression of FXYD6 protein and the age of the patients with hilar cholangiocarcinoma (Χ ~ 2 = 0.466, P = 0.495), lymph node metastasis (χ ~ 2 = 0.357, P = 0.550) P = 0.082). Conclusions The expression of FXYD6 in hilar cholangiocarcinoma is related to its differentiation degree, which may serve as a new tumor biomarker for hilar cholangiocarcinoma.